Ks logo

News & Insights

Subscribe
Icon search Icon close

  • People
  • OfficesIcon submenu
    • Icon submenu back back
    • Offices
    • North AmericaIcon submenu
      • Icon submenu back back
      • North America
      • Atlanta
      • Austin
      • Charlotte
      • Chicago
      • Denver
      • Houston
      • Los Angeles
      • Miami
      • New York
      • Northern Virginia
      • San Francisco
      • Silicon Valley
      • Washington, D.C.
    • Europe & Middle EastIcon submenu
      • Icon submenu back back
      • Europe & Middle East
      • Abu Dhabi
      • Brussels
      • Dubai
      • Frankfurt
      • Geneva
      • London
      • Paris
      • Riyadh
    • AsiaIcon submenu
      • Icon submenu back back
      • Asia
      • Singapore
      • Tokyo
  • CapabilitiesIcon submenu
    • Icon submenu back back
    • Capabilities
    • Corporate, Finance and InvestmentsIcon submenu
      • Icon submenu back back
      • Corporate, Finance and Investments
      • Overview
      • Activist Defense
      • Banking and Institutional Finance
      • Capital Markets
      • Construction and Procurement
      • Corporate Governance
      • Emerging Companies and Venture Capital
      • Employee Benefits and Executive Compensation
      • Energy and Infrastructure Projects
      • Financial Restructuring
      • Global Human Capital and Compliance
      • Investment Funds and Asset Management
      • Mergers and Acquisitions (M&A)
      • Middle East and Islamic Finance and Investment
      • Private Credit & Special Situations
      • Private Equity
      • Public Companies
      • Real Estate
      • Structured Finance and Securitization
      • Tax
      • Technology Transactions
    • Government MattersIcon submenu
      • Icon submenu back back
      • Government Matters
      • Overview
      • Antitrust
      • Data, Privacy and Security
      • Environmental, Health and Safety
      • FDA and Life Sciences
      • Government Advocacy and Public Policy
      • Government Contracts
      • Healthcare
      • International Trade
      • National Security and Corporate Espionage
      • Securities Enforcement and Regulation
      • Special Matters and Government Investigations
    • Trial and Global DisputesIcon submenu
      • Icon submenu back back
      • Trial and Global Disputes
      • Overview
      • Appellate, Constitutional and Administrative Law
      • Bankruptcy and Insolvency Litigation
      • Class Action Defense
      • Commercial Litigation
      • Construction and Engineering Disputes
      • Corporate and Securities Litigation
      • E-Discovery
      • Intellectual Property
      • International Arbitration and Litigation
      • Labor and Employment
      • Product Liability
      • Professional Liability
      • Toxic & Environmental Torts
    • Industries / IssuesIcon submenu
      • Icon submenu back back
      • Industries / Issues
      • Industries
      • Automotive, Transportation and Mobility
      • Energy
      • Financial Services
      • Food and Beverage
      • Franchise and Hospitality
      • Higher Education
      • Life Sciences and Healthcare
      • Technology
      • Issues
      • #MeToo
      • Buy American
      • COVID-19 Vaccine Rollout
      • Crisis Management
      • Environmental Agenda
      • Environmental, Social and Governance (ESG)
      • Focus on Women's Health
      • Russia/Ukraine
      • Special Purpose Acquisition Companies (SPACs)
      • The New Administration: Enforcement and Legislative Impact
  • CareersIcon submenu
    • Icon submenu back back
    • Careers
    • LawyersIcon submenu
      • Icon submenu back back
      • Lawyers
      • Experienced Lawyers
    • StudentsIcon submenu
      • Icon submenu back back
      • Students
      • Law Students
      • UK Graduate Recruitment
    • Judicial ClerksIcon submenu
      • Icon submenu back back
      • Judicial Clerks
      • Judicial Clerks
    • Other ProfessionalsIcon submenu
      • Icon submenu back back
      • Other Professionals
      • Other Professionals
  • News & InsightsIcon submenu
    • Icon submenu back back
    • News & Insights
    • NewsIcon submenu
      • Icon submenu back back
      • News
      • Cases & Deals
      • In the News
      • Press Releases
      • Recognitions
    • EventsIcon submenu
      • Icon submenu back back
      • Events
      • Conferences
      • Speaking Engagements
      • Webinars
    • InsightsIcon submenu
      • Icon submenu back back
      • Insights
      • Newsletters
      • Client Alerts
      • Thought Leadership
      • Articles
      • Feature
      • BLOGS
      • COVID-19 Vaccine Updates
      • China Subsidy Exchange
      • ESG Excellence
      • Energy Law Exchange
  • AboutIcon submenu
    • Icon submenu back back
    • About
    • Our FirmIcon submenu
      • Icon submenu back back
      • Our Firm
      • History
      • Our Values
    • Diversity & InclusionIcon submenu
      • Icon submenu back back
      • Diversity & Inclusion
      • Overview
      • Women’s Initiatives
      • Racial Diversity
      • LBGTQ+ Affinity
    • CitizenshipIcon submenu
      • Icon submenu back back
      • Citizenship
      • Overview
      • Pro Bono
      • Community Focus
  • Languages

News & Insights

  • NewsIcon submenu
    • Icon submenu back back
    • News
    • Cases & Deals
    • In the News
    • Press Releases
    • Recognitions
  • EventsIcon submenu
    • Icon submenu back back
    • Events
    • Conferences
    • Speaking Engagements
    • Webinars
  • InsightsIcon submenu
    • Icon submenu back back
    • Insights
    • Newsletters
    • Client Alerts
    • Thought Leadership
    • Articles
    • Feature
    • BLOGS
    • COVID-19 Vaccine Updates
    • China Subsidy Exchange
    • ESG Excellence
    • Energy Law Exchange
< Back to Bio
Icon close orange Beverly H. Lorell, M.D.

Insights 27 results

Client Alert

February 8, 2022
Europe - Between The EU Clinical Trials Regulation And The UK Guideline On Clinical Trials

Client Alert

November 9, 2021
A Magic Mixing Cauldron for the 21st Century: FDA’s new guidances on using real-world data in regulatory decision-making

Client Alert

July 26, 2021
FDA Issues New Draft Guidance for Sponsors on Safety Event Analysis and Reporting for IND and Bioavailability/Bioequivalence Studies

Client Alert

December 11, 2020
Department of Justice Vows Vigorous Enforcement of Clinical Trial Fraud

Client Alert

November 19, 2020
Heightened Focus on Foreign Influence in Academia

Client Alert

August 17, 2020
Federal Government Takes Steps Toward Enforcement of ClinicalTrials.gov Requirements

COVID-19 Vaccine Updates

June 10, 2020
Advice for Companies Attempting to Limit Liability from Vaccine Trials

Article · Source: Law360

June 10, 2020
COVID-19 Vaccine Developers Can Limit Liability From Trials

COVID-19 Vaccine Updates

May 27, 2020
Accelerated Covid-19 Vaccine Clinical Trials

Client Alert

May 27, 2020
Accelerated Covid-19 Vaccine Clinical Trials

Client Alert

March 23, 2020
U.S. and EU Regulators and Institutions Issue Guidance on Clinical Trial Conduct during COVID-19 Pandemic

Article · Source: Law360

March 19, 2020
Ruling In HHS Case May Mean More Drug Trial Reporting

© 2022 King & Spalding LLP
  • Contact Us
  • Disclaimer
  • Privacy Notice
  • Cookie Policy
  • Copyright Notice
  • Regulatory Notices
  • K&S Alumni Group